Viewing data from:

TREZIX

ANDA

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE | A204785 | KEY THERAPEUTICS LLC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Trezix (2023)

Total Spending

$57K

Total Claims

150

Beneficiaries

Avg Cost/Unit

$4.39

Spending Trend

$211K(2019)→$297K(2020)→$220K(2021)→$103K(2022)→$57K(2023)

YoY Change:+9.8%

5yr CAGR:+6.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Dec 3, 2014	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 320.5MG;30MG;16MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Nov 26, 2014

No patent or exclusivity listings for this strength.